Prostate Cancer International is
for 2011 by Great NonProfits
The abstracts of papers to be presented at the annual meeting of the American Urological Association are now available for scrutiny on-line — including by those who are not attending the meeting. Over the next week of so, The “New” Prostate Cancer InfoLink plans to read through these abstracts and comment on the ones that [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: category, Diagnosis, outcome, risk | 8 Comments »
A somewhat surprising paper from Johns Hopkins appears (unsurprisingly) to confirm what the Kattan pre-treatment nomogram has been telling us for years … that higher Gleason scores, higher PSA levels, higher clinical stage, and a higher proportion of biopsy cores being positive for prostate cancer are predictive of higher risk for post-surgical recurrence. metastasis, and [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: outcome, pathology, risk, surgery | 1 Comment »
The April issue of AUA News (a magazine only available to AUA members) includes an interesting article by David Penson, MD, in which he previews a lecture he will be giving at the upcoming annual meeting of the American Urological Association (in Atlanta, later this month).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: baseline, database, localized, outcone, regitry, standardized, trial | 6 Comments »
There has been a lot of media hype in Europe around the re-presentation of the PIVOT data by Dr. Wilt at the annual meeting of the European Association of Urology in Paris last week. And yet every prostate cancer specialist attending that meeting must have already been well aware of these data.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Management, obseration, PIVOT, risk, surgery, surveillance, Treatment | 8 Comments »
In the UK, the National Institute for Clinical Excellence (NICE) has just published guidance on the use of focal forms of high-intensity focused ultrasound (HIFU) for the treatment of (low- and intermediate-risk forms of) localized prostate cancer.
Filed under: Diagnosis, Management, Treatment | Tagged: focal, guidance, HIFU, high-intensity focused ultrasound, NICE | 5 Comments »
We finally appear to have mid-term follow-up data from a sizeable series of North American patients with low- and intermediate-risk prostate cancer treated with first-line, high-intensity focused ultrasound (HIFU). The follow-up is limited to a median of 2 years, however, which allows projection of outcomes at 4 years.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: HIFU, high-intensity focused ultrasound, outcomes | Leave a Comment »
According to a media release from Accuray, Inc., the company has initiated a multi-center, multinational clinical trial in Europe to compare the outcomes of patients with localized prostate cancer treated with CyberKnife stereotactic body radiation therapy (SBRT), da Vinci robot-assisted laparoscopic surgery (RALP), manual laparoscopic surgery (LRP), and conventionally fractionated intensity modulated radiation therapy (IMRT).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: CyberKnife, IMRT, radiation, SBRT, surgery, trial | 3 Comments »
A research letter just published in the Journal of the American Medical Association this week confirms what most physicians and prostate cancer advocates were already well aware of … that the U.S. Preventive Services Task Force (USPSTF) recommendation from 2008 — that men of 75 years and older should not generally be given annual PSA [...]
Filed under: Diagnosis, Risk | Tagged: Diagnosis, PSA, risk, screening | 2 Comments »
A new study available on line as a full-text article in European Urology has provided a retrospective analysis of the perioperative outcomes of men undergoing radical prostatectomy for localized prostate cancer in a 15-month period between October 2008 and December 2009 at 20 percent of the community hospitals in the USA (including public hospitals and [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: comparison, open, outcome, radical prostatectomy, RALP, robot-assisted | Leave a Comment »
An analysis published by Kamel et al. in the Journal of Urology earlier this year offers an estimate of the potential years of life lost (PYLL) due to prostate cancer in seven 5-year periods between 1972 and 2006. (Prostate cancer was the most prevalent of several forms of urogenital cancer addressed in this report.)
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: life, lost, potential, PYLL, years | Leave a Comment »
As many readers will be aware, the Sage of Omaha, Warren Buffett, chairman and CEO of Berkshire Hathaway, announced yesterday that he has been diagnosed with prostate cancer that is “not remotely life threatening.” He does intend, however, to undergo 8 weeks of radiation therapy. Mr. Buffet is 81 years of age.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Buffett, Diagnosis, Management, risk | 6 Comments »
The April issue of the Journal of the Canadian Urologic Association offers the interested reader access to the full texts of a small number of topical articles. None of them could be considered “game changing” in terms of current prostate cancer management today … but certainly thought-stimulating.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: adjuvant, biopsy, Diagnosis, Prevention, radiation, risk, salvage | Leave a Comment »
An new article on line in the Proceedings of the National Academy of Sciences or PNAS has further extended our understanding of the genetic and inheritable factors that may predispose individual patients to higher risk for clinically significant and aggressive forms of prostate cancer
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: CNV, copy number variant, Diagnosis, gene, heredity, risk | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site